

Addendum

Addendum: Correlation between PD-L1 expression and *MET* gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver

Marta Domènech^{1,3}, Ana M. Muñoz Marmol², Jose Luis Mate², Anna Estival^{1,3}, Teresa Moran^{1,3}, Marc Cucurull^{1,3}, Maria Saigi^{1,3}, Ainhoa Hernandez^{1,3}, Carolina Sanz², Alba Hernandez-Gallego², Aintzane Urbizu², Anna Martinez-Cardus³, Adrià Bernat³ and Enric Carcereny^{1,3}

¹Medical Oncology Department, Catalan Institute of Oncology Badalona, Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain

²Pathology Department, Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain

³Badalona Applied Research Group in Oncology (BARGO), Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain

Published:

Copyright: © 2023 Domènech et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: No funding was used for this publication.

Original article: Oncotarget. 2021; 12:1802–1810. <https://doi.org/10.18632/oncotarget.28045>